PubMed Health⌕ Search

PubMed · 10628439

Methodology for analyzing episodic events.

Abstract

Many health outcomes of interest to occupational epidemiologists are common recurrent health events. Epidemiologic approaches to the study of such health events are reviewed. Episodic events are considered to be events that occur at a distinct point in time - either with sudden onset or the sudden crossing of a threshold of detection - and they must be reversible events that can recur in the same person in response to a proximate trigger. Studying such health events poses 4 challenges to existing methods: (i) key epidemiologic concepts, such as incidence, do not naturally accommodate recurrent events, (ii) study designs must capture time-varying exposures, (iii) statistical models must be able to handle correlated outcomes, and (iv) feedback bias must be addressed. In response, methods such as longitudinal studies, case-crossover designs and generalized estimating equations are identified as appropriate tools.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

E A Eisen. 1999. Methodology for analyzing episodic events.. https://pubmed.ncbi.nlm.nih.gov/10628439/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Expression of survivin in HTLV-I-infected T-cell lines and primary ATL cells.

Human T-cell leukemia virus type I (HTLV-I) is the etiological agent of adult T-cell leukemia (ATL), although the precise mechanisms involved in the transformation process have not yet been defined. Deregulated inhibition of apoptosis may facilitate the insurgence of leukemia. Survivin is an inhibitor of apoptosis and considered to play a role in oncogenesis. We investigated the expression of survivin in HTLV-I-infected T-cell lines and primary ATL cells. Northern blot analysis showed expression of survivin transcript in all 9 HTLV-I-positive T-cell lines. High survivin expression levels were detected in primary cells of patients with acute-type ATL, but no such expression was noted in the cells of chronic-type ATL or normal peripheral blood mononuclear cells. Treatment of an HTLV-I-infected T-cell line, MT-1, with survivin specific antisense oligonucleotide resulted in reduced cell growth. Our results suggest that expression of survivin may play an important role in the development and pathogenesis of ATL.

Acute Disease↗

Donor-derived IP-10 initiates development of acute allograft rejection.

An allograft is often considered an immunologically inert playing field on which host leukocytes assemble and wreak havoc. However, we demonstrate that graft-specific physiologic responses to early injury initiate and promulgate destruction of vascularized grafts. Serial analysis of allografts showed that intragraft expression of the three chemokine ligands for the CXC chemo-kine receptor CXCR3 was induced in the order of interferon (IFN)-gamma-inducible protein of 10 kD (IP-10, or CXCL10), IFN-inducible T cell alpha-chemoattractant (I-TAC; CXCL11), and then monokine induced by IFN-gamma (Mig, CXCL9). Initial IP-10 production was localized to endothelial cells, and only IP-10 was induced by isografting. Anti-IP-10 monoclonal antibodies prolonged allograft survival, but surprisingly, IP-10-deficient (IP-10(-/-)) mice acutely rejected allografts. However, though allografts from IP-10(+/+) mice were rejected by day 7, hearts from IP-10(-/-) mice survived long term. Compared with IP-10(+/+) donors, use of IP-10(-/-) donors reduced intragraft expression of cytokines, chemokines and their receptors, and associated leukocyte infiltration and graft injury. Hence, tissue-specific generation of a single chemokine in response to initial ischemia/reperfusion can initiate progressive graft infiltration and amplification of multiple effector pathways, and targeting of this proximal chemokine can prevent acute rejection. These data emphasize the pivotal role of donor-derived IP-10 in initiating alloresponses, with implications for tissue engineering to decrease immunogenicity, and demonstrate that chemokine redundancy may not be operative in vivo.

Acute Disease↗